trial · primary record
Lenvatinib
Hepatocellular Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2029-05-31 |
| Primary endpoint | 1-year progression-free survival (PFS) by mRECIST |
| Registry ID | NCT07827807 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:05.579Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07827807
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.